Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Results

Catalyst Pharmaceuticals Beats on EPS, Stock Down 1.94%

Catalyst Pharmaceuticals reported a strong EPS performance, exceeding expectations by over 25%. However, the stock reacted negatively, dropping nearly 2% in response to the lack of revenue guidance and overall market sentiment. Investors may be cautious without clearer future projections from management.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.68	N/A	+25.23%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their focus on long-term strategies. However, they did not provide any guidance for future revenue.

We are pleased with our EPS performance this quarter.

While we did not provide revenue guidance, we remain focused on our strategic initiatives.

Catalyst Pharmaceuticals Beats on EPS, Stock Down 1.94%

Key numbers

Management commentary

Catalyst Pharmaceuticals, Inc.

More earnings this week

Catalyst Pharmaceuticals Beats on EPS, Stock Down 1.94%

Key numbers

Management commentary